Safety and Durability of Sirolimus for Treatment of LAM

Overview

About this study

The MIDAS study aims to follow women with LAM who are currently taking, have previously failed or been intolerant of, or are considering treatment with mTOR inhibitors sirolimus or everolimus as part of their clinical care.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • LAM patient, age 18+ years or older; OR
  • Female TSC patient, age 18+ years or older with or without cystic lungs.
  • Diagnosis of LAM or TSC.
    Ability to understand and sign informed consent form.
  • Currently on mTOR inhibitors, previously intolerant of or have failed mTOR inhibitors, or may be considered for mTOR therapy in the future.

Exclusion Criteria:

  • Inability to attend at least one clinic visit per year for LAM evaluation.
  • Inability to give informed consent
  • Previous lung transplant.
  • Inability or unwillingness to perform pulmonary function testing.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Misbah Baqir, M.B.B.S.

Contact us for the latest status

Contact information:

Boleyn Andrist CCRP

(507)284-9946

Andrist.Boleyn@mayo.edu

Jacksonville, Fla.

Mayo Clinic principal investigator

Charles Burger, M.D.

Closed for enrollment

Contact information:

Inna Dawson CCRP

(904)953-3855

Abrea.Inna@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20425082

Mayo Clinic Footer